Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion
What the film says
When large B-cell lymphoma keeps growing right up to the day CAR T therapy begins, most patients relapse within a year.
The idea: clear the debris that shields the tumor, so the CAR T cells can reach it.
Neutrophils can throw out sticky webs of DNA called NETs. In lymphoma, those webs feed tumor growth, track with worse outcomes, and may block T cells. CLS-015 is a recombinant DNase, an enzyme that digests them, given by vein five times over the two weeks after a standard CD19 CAR T infusion.
A small first safety study at Sourasky Medical Center in Tel Aviv, for patients still progressing at lymphodepletion. Ron Ram leads it. Public record; not medical advice.
Sources behind this film
SD/PD at lymphodepletion → 1-year PFS 20–30%; NETs impede CAR T penetration; CLS-015 enzymatically degrades NETs; rhDNase I IV on days 0, 3, 6, 10, 15 after CAR T; Standard CD19 CAR T products (tisa-cel, axi-cel, liso-cel) (+1 more lines)
Nie M. Clin Cancer Res, 2019
NETs promote DLBCL progression, associated with worse outcome
The drug
CLS-015 IV infusions after CAR-T infusion done on Days 0,3,6,10 and 15 after CAR-T infusion
Disease progression in large B-cell lymphoma is a major obstacle to successful CAR-T therapy, with approximately 40% of patients experiencing disease progression within 3 months of CAR-T infusion and 60% of patients experiencing disease progression within the first year.
While patients with large B-cell lymphoma in partial response or complete response during lymphodepletion have a progression-free survival (PFS) of 60-80% at 1 year, patients with stable disease (SD) or progressive disease (PD) in the lymphodepletion phase have a poor PFS of 20-30%.
The study
This is a Phase 1, single-center, open-label study to evaluate the safety of CLS-015 in combination with anti-CD19 CAR-T therapy in patients with large B-cell lymphoma. The goal is to improve clinical response by reversing the negative effects of NETs on immune function and CAR-T cells.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.